Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDE196 + binimetinib
- Development stage
- Unknown
- Lead developer
- IDEAYA Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of **darovasertib (IDE196)**, a selective small molecule **protein kinase C (PKC) inhibitor**, and **binimetinib (Mektovi)**, a **MEK inhibitor**, developed for the treatment of solid tumors harboring GNAQ or GNA11 mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Darovasertib inhibits the PKC pathway, a key oncogenic pathway in these cancers, while binimetinib inhibits the MEK component of the MAPK pathway, providing preclinically suggested synergistic antitumor activity. This combination is being evaluated in a multi-arm Phase 1/2 clinical trial for safety, tolerability, pharmacokinetics, and anti-tumor efficacy[1][3][4].
- Brand names
- Mektovi
- Other names
- darovasertib + binimetinibIDE196 + MEK162
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)PKC (Protein kinase C family)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)
Beyond the preview
Go deeper on IDE196 + binimetinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDE196 + binimetinib.